Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Tirzepatide is also the compound in the diabetes drug Mounjaro. Advertising Even before the FDA approval, some doctors have ...

The FDA approval comes amid growing discussion about the potential uses of weight loss drugs beyond treating obesity and ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...

The FDA approval for sleep apnea is ... That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug also saw reductions in blood pressure and ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...